全身投与用 AteloGene® Systemic Use | 株式会社高研

製品リストを表示

全身投与用 AteloGene® Systemic Use

概要

本製品はマウスへの全身投与により siRNA/miRNA を生体組織中へデリバリーし、効率よく細胞内へ導入するためのキットです。
「AteloGene®」の主成分であるアテロコラーゲンは、正に荷電しているため、適切な濃度と割合で核酸と混合することにより、 静電的に複合体を形成します。そして、複合体形成により、核酸分解酵素による核酸の分解を防ぐことが可能です 。

アテロコラーゲンとは

用途

 

  • 核酸の尾静脈投与

  • 核酸の腹腔内投与

 

特長

  • 「AteloGene®」の主成分であるアテロコラーゲンは、siRNA/miRNAと複合体を形成するため、RNAi効果が長続きします。
  • 「AteloGene®」はアテロコラーゲンから作られているため、無毒性です。
  • 「AteloGene ® Systemic Use」はゲル化しない性質のため、尾静脈投与により全身へsiRNA/miRNAを効率良くデリバリーすることが可能です。

キットの内容

①AteloGene® Systemic Useプレフィルドシリンジ
  (調製中のロスも含めて600μLで5回投与分)
600 μL入り × 2 本
②10×siRNAバッファー (miRNAにも使用可) 3 mL × 1 本
③滅菌水 3 mL × 1 本
④2mLマイクロチューブ 2本
⑤ディスポーザブルシリンジ 2本
⑥18G注射針 4本
⑦26G注射針 2本
⑧取扱説明書 1冊

キット以外に必要な機器・試薬

  • siRNA/miRNA(AteloSiLence in vivo 用siRNA/miRNAのようなPAGE精製または HPLC精製グレード)
  • siRNA/miRNA調製用容器(滅菌済み、RNase free)
  • 保冷具(クラッシュアイス、コールドブロックなど)
  • ローテーター(転倒攪拌できるもの、TAITEC RT-5、Bibby scientific SB3など)
  • ピペッターおよびチップ(滅菌済み、RNase free)
  • 高速冷却遠心機
  • 麻酔薬

保管方法:冷蔵(2~10°C) 
有効期限:箱側面に記載の製造日より5年間※
※キット付属品の保証期限に合わせるため、平成30年1月頃より3年に変更予定。

製品番号 製品 包装 価格(税別)
#1391 AteloGene® Systemic Use 1キット(10回投与分※) ¥60,000

本品は研究用試薬です。
※200μL/回として算出しているため、対象組織によっては10回以上使用可能な場合もあります。

使用例

【AteloGene® Systemic Useを用いたマウス全身転移がんモデルへのsiRNA全身投与】

マウスの全身に転移したルシフェラーゼ発現がん細胞に対し、「AteloGene®」を使用してルシフェラーゼsiRNA(Luc siRNA)を投与したとき、Luc siRNA単独投与に比べ、高いルシフェラーゼ発現抑制を示した。

参考文献

  • がん関連全身投与例
  • その他全身投与例
    • miR-340 suppresses tumor growth and enhances chemosensitivity of colorectal cancer by targeting RLIP76.
      Zhang LL, Xie FJ, Tang CH, Xu WR, Ding XS, Liang J.
      Eur Rev Med Pharmacol Sci. 2017 Jun;21(12):2875-2886. PMID: 28682430
    • Efficient delivery of micro RNA to bone-metastatic prostate tumors by using aptamer-conjugated atelocollagen in vitro and in vivo.
      Hao Z, Fan W, Hao J, Wu X, Zeng GQ, Zhang LJ, Nie SF, Wang XD.
      Drug Deliv. 2016;23(3):874-81. PMID: 24892627
    • MiR675-5p Acts on HIF-1α to Sustain Hypoxic Responses: A New Therapeutic Strategy for Glioma.
      Lo Dico A, Costa V, Martelli C, Diceglie C, Rajata F, Rizzo A, Mancone C, Tripodi M, Ottobrini L, Alessandro R, Conigliaro A.
      Theranostics. 2016 May 8;6(8):1105-18. PMID: 27279905
    • Identification of Akt1 as a potent therapeutic target for oral squamous cell carcinoma.
      Nakashiro K, Tanaka H, Goda H, Iwamoto K, Tokuzen N, Hara S, Onodera J, Fujimoto I, Hino S, Hamakawa H.
      Int J Oncol. 2015 Oct;47(4):1273-81. PMID: 26315674
    • Atelocollagen-mediated intravenous siRNA delivery specific to tumor tissues orthotopically xenografted in prostates of nude mice and its anticancer effects.
      Yuan Y, Makita N, Cao D, Mihara K, Kadomatsu K, Takei Y.
      Nucleic Acid Ther. 2015 Apr;25(2):85-94. PMID: 25692652
    • Specific inhibition of tumor cells by oncogenic EGFR specific silencing by RNA interference.
      Takahashi M, Chiyo T, Okada T, Hohjoh H.
      PLoS One. 2013 Aug 8;8(8):e73214. PMID: 23951344
    • Targeting Aurora kinase A suppresses the growth of human oral squamous cell carcinoma cells in vitro and in vivo.
      Tanaka H, Nakashiro KI, Iwamoto K, Tokuzen N, Fujita Y, Shirakawa R, Oka R, Goda H, Hamakawa H.
      Oral Oncol. 2013 Jun;49(6):551-9. PMID: 23481312
    • Intraperitoneal delivery of a small interfering RNA targeting NEDD1 prolongs the survival of scirrhous gastric cancer model mice.
      Fujita T, Yanagihara K, Takeshita F, Aoyagi K, Nishimura T, Takigahira M, Chiwaki F, Fukagawa T, Katai H, Ochiya T, Sakamoto H, Konno H, Yoshida T, Sasaki H.
      Cancer Sci. 2013 Feb;104(2):214-22. PMID: 23106787
    • Effect of ADAM28 on Carcinoma Cell Metastasis by Cleavage of von Willebrand Factor.
      Mochizuki S, Soejima K, Shimoda M, Abe H, Sasaki A, Okano HJ, Okano H, Okada Y.
      J Natl Cancer Inst. 2012 Jun 20;104(12):906-22. PMID:22636800
    • siRNA targeting Livin decreases tumor in a xenograft model for colon cancer.
      Oh BY, Lee RA, Kim KH.
      World J Gastroenterol. 2011 May 28;17(20):2563-71. PMID:21633662
    • MicroRNA-143 regulates human osteosarcoma metastasis by regulating matrix metalloprotease-13 expression.
      Osaki M, Takeshita F, Sugimoto Y, Kosaka N, Yamamoto Y, Yoshioka Y, Kobayashi E, Yamada T, Kawai A, Inoue T, Ito H, Oshimura M, Ochiya T.
      Mol Ther. 2011 Jun;19(6):1123-30. PMID:21427707
    • Anti-tumor effect of small interfering RNA targeting the androgen receptor in human androgen-independent prostate cancer cells.
      Azuma K, Nakashiro K, Sasaki T, Goda H, Onodera J, Tanji N, Yokoyama M, Hamakawa H.
      Biochem Biophys Res Commun. 2010 Jan 1;391(1):1075-9. PMID:20004643
    • Rb inactivation accelerates neoplastic growth and substitutes for recurrent amplification of cIAP1, cIAP2 and Yap1 in sporadic mammary carcinoma associated with p53 deficiency.
      Cheng L, Zhou Z, Flesken-Nikitin A, Toshkov IA, Wang W, Camps J, Ried T, Nikitin AY.
      Oncogene. 2010 Oct 21;29(42):5700-11. PMID:20676140
    • Knockdown of Akt isoforms by RNA silencing suppresses the growth of human prostate cancer cells in vitro and in vivo.
      Sasaki T, Nakashiro K, Tanaka H, Azuma K, Goda H, Hara S, Onodera J, Fujimoto I, Tanji N, Yokoyama M, Hamakawa H.
      Biochem Biophys Res Commun. 2010 Aug 13;399(1):79-83. PMID:20638364
    • Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes.
      Takeshita F, Patrawala L, Osaki M, Takahashi RU, Yamamoto Y, Kosaka N, Kawamata M, Kelnar K, Bader AG, Brown D, Ochiya T.
      Mol Ther. 2010 Jan;18(1):181-7. PMID:19738602.
    • Systemic delivery of siRNA specific to tumor mediated by atelocollagen: combined therapy using siRNA targeting Bcl-xL and cisplatin against prostate cancer.
      Mu P, Nagahara S, Makita N, Tarumi Y, Kadomatsu K, Takei Y.
      Int J Cancer. 2009 Dec 15;125(12):2978-90. PMID:19422046
    • Glutathione S-transferase Pi mediates proliferation of androgen-independent prostate cancer cells.
      Hokaiwado N, Takeshita F, Naiki-Ito A, Asamoto M, Ochiya T, Shirai T.
      Carcinogenesis. 2008 Jun;29(6):1134-8. PMID: 18413363
    • Administration of PLK-1 small interfering RNA with atelocollagen prevents the growth of liver metastases of lung cancer.
      Kawata E, Ashihara E, Kimura S, Takenaka K, Sato K, Tanaka R, Yokota A, Kamitsuji Y, Takeuchi M, Kuroda J, Tanaka F, Yoshikawa T, Maekawa T.
      Mol Cancer Ther. 2008 Sep;7(9):2904-12. PMID: 18790771
    • Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo.
      Takeshita F, Minakuchi Y, Nagahara S, Honma K, Sasaki H, Hirai K, Teratani T, Namatame N, Yamamoto Y, Hanai K, Kato T, Sano A, Ochiya T.
      Proc Natl Acad Sci U S A. 2005 Aug 23;102(34):12177-82. PMID:16091473
    • Protective Effect of Let-7 miRNA Family in Regulating Inflammation in Diabetes-Associated Atherosclerosis.
      Brennan E, Wang B, McClelland A, Mohan M, Marai M, Beuscart O, Derouiche S, Gray S, Pickering R, Tikellis C, de Gaetano M, Barry M, Belton O, Ali-Shah ST, Guiry P, Jandeleit-Dahm KA, Cooper ME, Godson C, Kantharidis P.
      Diabetes. 2017 Aug;66(8):2266-2277. PMID: 28487436
    • Signal transducer and activator of transcription 5 plays a crucial role in hepatic lipid metabolism through regulation of CD36 expression.
      Hosui A, Tatsumi T, Hikita H, Saito Y, Hiramatsu N, Tsujii M, Hennighausen L, Takehara T.
      Hepatol Res. 2017 Jul;47(8):813-825. PMID: 27593674
    • Deficiency in catechol-o-methyltransferase is linked to a disruption of glucose homeostasis in mice.
      Kanasaki M, Srivastava SP, Yang F, Xu L, Kudoh S, Kitada M, Ueki N, Kim H, Li J, Takeda S, Kanasaki K, Koya D.
      Sci Rep. 2017 Aug 11;7(1):7927. PMID: 28801594
    • MicroRNAs 106b and 222 Improve Hyperglycemia in a Mouse Model of Insulin-Deficient Diabetes via Pancreatic β-Cell Proliferation.
      Tsukita S, Yamada T, Takahashi K, Munakata Y, Hosaka S, Takahashi H, Gao J, Shirai Y, Kodama S, Asai Y, Sugisawa T, Chiba Y, Kaneko K, Uno K, Sawada S, Imai J, Katagiri H.
      EBioMedicine. 2017 Feb;15:163-172. PMID: 27974246
    • MiR-29a Assists in Preventing the Activation of Human Stellate Cells and Promotes Recovery From Liver Fibrosis in Mice.
      Matsumoto Y, Itami S, Kuroda M, Yoshizato K, Kawada N, Murakami Y.
      Mol Ther. 2016 Oct;24(10):1848-1859. PMID: 27480597
    • Role of Sialidase in Long-Term Potentiation at Mossy Fiber-CA3 Synapses and Hippocampus-Dependent Spatial Memory.
      Minami A, Saito M, Mamada S, Ieno D, Hikita T, Takahashi T, Otsubo T, Ikeda K, Suzuki T.
      PLoS One. 2016 Oct 26;11(10):e0165257. PMID: 27783694
    • MicroRNA-124 inhibits the progression of adjuvant-induced arthritis in rats.
      Nakamachi Y, Ohnuma K, Uto K, Noguchi Y, Saegusa J, Kawano S.
      Ann Rheum Dis. 2016 Mar;75(3):601-8. PMID: 25596157
    • Pivotal Role of Carbohydrate Sulfotransferase 15 in Fibrosis and Mucosal Healing in Mouse Colitis.
      Suzuki K, Arumugam S, Yokoyama J, Kawauchi Y, Honda Y, Sato H, Aoyagi Y, Terai S, Okazaki K, Suzuki Y, Mizumoto S, Sugahara K, Atreya R, Neurath MF, Watanabe K, Hashiguchi T, Yoneyama H, Asakura H.
      PLoS One. 2016 Jul 13;11(7):e0158967. PMID: 27410685
    • Involvement of Hydrogen Sulfide in Endothelium-Derived Relaxing Factor-Mediated Responses in Rat Cerebral Arteries.
      Wang M, Hu Y, Fan Y, Guo Y, Chen F, Chen S, Li Q, Chen Z.
      J Vasc Res. 2016 Oct 13;53(3-4):172-185. PMID: 27732975
    • RNA interference targeting carbohydrate sulfotransferase 3 diminishes macrophage accumulation, inhibits MMP-9 expression and promotes lung recovery in murine pulmonary emphysema.
      Kai Y, Tomoda K, Yoneyama H, Yoshikawa M, Kimura H.
      Respir Res. 2015 Dec 9;16:146. PMID: 26646821
    • Eomesodermin-expressing T-helper cells are essential for chronic neuroinflammation.
      Raveney BJ, Oki S, Hohjoh H, Nakamura M, Sato W, Murata M, Yamamura T.
      Nat Commun. 2015 Oct 5;6:8437. PMID: 26436530
    • MicroRNA-451 down-regulates neutrophil chemotaxis via p38 MAPK.
      Murata K, Yoshitomi H, Furu M, Ishikawa M, Shibuya H, Ito H, Matsuda S.
      Arthritis Rheumatol. 2014 Mar;66(3):549-59. PMID: 24574214
    • Efficient Delivery of siRNA by Atelocollagen in a Murine Laser-Induced Choroidal Neovascularization Model.
      Ito Y, Nozaki M, Sugitani K, Ashikari M, Hirano Y, Ogura Y.
      Ophthalmologica. 2013;230(4):215-21. PMID: 24080835
    • The Downregulation of microRNA let-7a Contributes to the Excessive Expression of Type I Collagen in Systemic and Localized Scleroderma.
      Makino K, Jinnin M, Hirano A, Yamane K, Eto M, Kusano T, Honda N, Kajihara I, Makino T, Sakai K, Masuguchi S, Fukushima S, Ihn H.
      J Immunol. 2013 Apr 15;190(8):3905-15. PMID: 23509348
    • Nuclear Receptor NR4A2 Orchestrates Th17 Cell-Mediated Autoimmune Inflammation via IL-21 Signalling.
      Raveney BJ, Oki S, Yamamura T.
      PLoS One. 2013;8(2):e56595. PMID: 23437182
    • Effects of Atelocollagen Formulation Containing Oligonucleotide on Endothelial Permeability.
      Koji Hanai, Takashi Kojima, Mika Ota, Jun Onodera, and Norimasa Sawada, Journal of J Drug Deliv. 2012;2012:245835. PMID: 22506120
    • Atelocollagen-mediated Systemic Delivery Prevents Immunostimulatory Adverse Effects of siRNA in Mammals.
      Inaba S, Nagahara S, Makita N, Tarumi Y, Ishimoto T, Matsuo S, Kadomatsu K, Takei Y.
      Mol Ther. 2012 Feb;20(2):356-66 PMID:22031237
    • Manipulation of CD98 Resolves Type 1 Diabetes in NOD Mice.
      Lian G, Arimochi H, Kitamura A, Nishida J, Li S, Kishihara K, Maekawa Y, Yasutomo K.
      J Immunol. 2012 Mar 1;188(5):2227-34 PMID:22291182
    • MicroRNA-181b regulates NF-κB-mediated vascular inflammation.
      Sun X, Icli B, Wara AK, Belkin N, He S, Kobzik L, Hunninghake GM, Vera MP, Blackwell TS, Baron RM, Feinberg MW.
      J Clin Invest. 2012 Jun 1;122(6):1973-90. PMID:22622040
    • Reduction of Type IV Collagen by Upregulated miR-29 in Normal Elderly Mouse and klotho-Deficient, Senescence-Model Mouse.
      Takahashi M, Eda A, Fukushima T, Hohjoh H.
      PLoS One. 2012;7(11):e48974. PMID: 23139829
    • Mechanisms of the hepatoprotective effects of tamoxifen against drug-induced and chemical-induced acute liver injuries.
      Yoshikawa Y, Miyashita T, Higuchi S, Tsuneyama K, Endo S, Tsukui T, Toyoda Y, Fukami T, Nakajima M, Yokoi T.
      Toxicol Appl Pharmacol. 2012 Oct 1;264(1):42-50. PMID:22841776
    • Atelocollagen-mediated systemic administration of myostatin-targeting siRNA improves muscular atrophy in caveolin-3-deficient mice.
      Kawakami E, Kinouchi N, Adachi T, Ohsawa Y, Ishimaru N, Ohuchi H, Sunada Y, Hayashi Y, Tanaka E, Noji S.
      Dev Growth Differ. 2011 Jan;53(1):48-54. PMID:21261610
    • The inhibitory effect of microRNA-146 expression on bone destruction in arthritis.
      Nakasa T, Shibuya H, Nagata Y, Niimoto T, Ochi M.
      Arthritis Rheum. 2011 Jun;63(6):1582-90.  PMID:21425254
    • Chondroitin sulphate N-acetylgalactosaminyl-transferase-1 inhibits recovery from neural injury.
      Takeuchi K, Yoshioka N, Higa Onaga S, Watanabe Y, Miyata S, Wada Y, Kudo C, Okada M, Ohko K, Oda K, Sato T, Yokoyama M, Matsushita N, Nakamura M, Okano H, Sakimura K, Kawano H, Kitagawa H, Igarashi M.
      Nat Commun. 2013;4:2740. PMID: 24220492
    • Cathepsin L inhibition prevents murine autoimmune diabetes via suppression of CD8(+) T cell activity.
      Yamada A, Ishimaru N, Arakaki R, Katunuma N, Hayashi Y.
      PLoS One. 2010 Sep 22;5(9):e12894. PMID:20877570
    • Downregulation of monocyte chemoattractant protein-1 involving short interfering RNA attenuates hapten-induced contact hypersensitivity.
      Ishimoto T, Takei Y, Yuzawa Y, Hanai K, Nagahara S, Tarumi Y, Matsuo S, Kadomatsu K.
      Mol Ther. 2008 Feb;16(2):387-95. PMID:18059372
    • Atelocollagen-mediated local and systemic applications of myostatin-targeting siRNA increase skeletal muscle mass.
      Kinouchi N, Ohsawa Y, Ishimaru N, Ohuchi H, Sunada Y, Hayashi Y, Tanimoto Y, Moriyama K, Noji S.
      Gene Ther. 2008 Aug;15(15):1126-30. PMID:18323791
    • Potential of atelocollagen-mediated systemic antisense therapeutics for inflammatory disease.
      Hanai K, Kurokawa T, Minakuchi Y, Maeda M, Nagahara S, Miyata T, Ochiya T, Sano A.
      Hum Gene Ther. 2004 Mar;15(3):263-72. PMID:15018735